Skip to main content
Erschienen in: Infection 6/2020

20.08.2020 | Original Paper

Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy

verfasst von: Mohammad El-Sayed, Zeinab Abdellatif, Aisha Elsharkawy, Mohamed El Kassas, Reham Abd Elmoniem, Amaal Marzouk, Rabab Fouad, Gamal Esmat, Shereen Abdel Alem

Erschienen in: Infection | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of SOF-based therapy on renal functions is quite controversial in clinical practice. Therefore, we aimed to evaluate the serial changes of renal indices during SOF-based therapy in CHC patients with normal kidney function or mild renal impairment.

Methods

We retrospectively reviewed all CHC patients who received different SOF-based regimens from January 2015 until December 2017, and presented with a baseline eGFR ≥ 30 ml/min/1.73m2. Patients who didn't achieve SVR, with missing creatinine or eGFR data, and patients with eGFR less than 30 ml/min/1.73m2 at baseline were excluded. eGFR was calculated for each time of evaluation using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.

Results

A total of 1004 patients were finally included. The mean serum creatinine and eGFR levels varied between 0.84 mg/dl and 106.53 ml/min/1.73m2 for baseline and 0.87 mg/dl and 104.24 ml/min/1.73m2 for SVR12, respectively. The maximum increase of creatinine was 3.69 mg/dl and the maximum decrease of eGFR level was 83.30 ml/min/1.73m2 during treatment. Moreover, 74.4% of treated patients stayed in the same eGFR category, 14.3% progressed to a higher eGFR category, and 11.3% had an improvement eGFR category at EOT and continued to SVR12. Age > 65 years, baseline eGFR, and ribavirin–containing regimens were independent risk factors of eGFR decline during and after SOF-based treatment.

Conclusion

SOF-based therapies seem to be safe in CHC patients with baseline normal or slightly impaired renal function.
Literatur
1.
Zurück zum Zitat World Health Organization. Global Hepatitis Report 2017. Geneva: 2017. World Health Organization. Global Hepatitis Report 2017. Geneva: 2017.
2.
Zurück zum Zitat Fabrizi F, Plaisier E, Saadoun D, Martin P, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61(4):623–37.CrossRef Fabrizi F, Plaisier E, Saadoun D, Martin P, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013;61(4):623–37.CrossRef
3.
Zurück zum Zitat Daniel KE, Saeian K, Rizvi S, et al. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat. 2020;27(2):195–204.CrossRef Daniel KE, Saeian K, Rizvi S, et al. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. J Viral Hepat. 2020;27(2):195–204.CrossRef
4.
Zurück zum Zitat Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–70.CrossRef Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–70.CrossRef
5.
Zurück zum Zitat Gane EJ, Robson RA, Bonacini M, et al. Safety, antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Hepatology. 2014;60(Suppl. 1):667A. Gane EJ, Robson RA, Bonacini M, et al. Safety, antiviral efficacy and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Hepatology. 2014;60(Suppl. 1):667A.
6.
Zurück zum Zitat D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, et al. Renal safety in 3264 HCV patients treated with DAA-based regimens: results from a large Italian real-life study. Dig Liver Dis. 2020;52(2):190–8.CrossRef D'Ambrosio R, Pasulo L, Giorgini A, Spinetti A, et al. Renal safety in 3264 HCV patients treated with DAA-based regimens: results from a large Italian real-life study. Dig Liver Dis. 2020;52(2):190–8.CrossRef
7.
Zurück zum Zitat Liu CH, Lee MH, Lin JW, Liu CJ, et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals. J Hepatol. 2020;72(5):839–46.CrossRef Liu CH, Lee MH, Lin JW, Liu CJ, et al. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals. J Hepatol. 2020;72(5):839–46.CrossRef
8.
Zurück zum Zitat Butt AA, Ren Y, Marks K, Shaikh OS, Sherman KE, ERCHIVES study. Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Aliment Pharmacol Ther. 2017;45:150–9.CrossRef Butt AA, Ren Y, Marks K, Shaikh OS, Sherman KE, ERCHIVES study. Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Aliment Pharmacol Ther. 2017;45:150–9.CrossRef
9.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1–S93. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1–S93.
10.
Zurück zum Zitat Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis inpatients with HIV/HCV co-infection. Hepatology. 2006;43:1317–25.CrossRef Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis inpatients with HIV/HCV co-infection. Hepatology. 2006;43:1317–25.CrossRef
11.
Zurück zum Zitat Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRef Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRef
12.
Zurück zum Zitat Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.CrossRef Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.CrossRef
13.
Zurück zum Zitat Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, et al. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol. 2019;13(10):1009–166.CrossRef Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, et al. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol. 2019;13(10):1009–166.CrossRef
14.
Zurück zum Zitat The Polaris Observatory. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.CrossRef The Polaris Observatory. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.CrossRef
15.
Zurück zum Zitat Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.CrossRef Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.CrossRef
16.
Zurück zum Zitat Pybus OG, Drummond AJ, Nakano T, et al. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol. 2003;20:381–7.CrossRef Pybus OG, Drummond AJ, Nakano T, et al. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol. 2003;20:381–7.CrossRef
17.
Zurück zum Zitat Taneja S, Duseja A, De A, Mehta M, et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63:1334–400.CrossRef Taneja S, Duseja A, De A, Mehta M, et al. Low-dose sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63:1334–400.CrossRef
18.
Zurück zum Zitat Fabrizi F, Martin P, Messa P, et al. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988–94.CrossRef Fabrizi F, Martin P, Messa P, et al. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant. Kidney Int. 2016;89:988–94.CrossRef
19.
Zurück zum Zitat Eletreby R, El-Serafy M, Anees M, Kasem G, et al. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int. 2020;40(4):797–805.CrossRef Eletreby R, El-Serafy M, Anees M, Kasem G, et al. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int. 2020;40(4):797–805.CrossRef
20.
Zurück zum Zitat Alvarez-Ossorio MJ, Sarmento E, Castro R, et al. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. J Viral Hepat. 2018;25(6):699–706.CrossRef Alvarez-Ossorio MJ, Sarmento E, Castro R, et al. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. J Viral Hepat. 2018;25(6):699–706.CrossRef
21.
Zurück zum Zitat Brennan BJ, Wang K, Blotner S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57:6097–105.CrossRef Brennan BJ, Wang K, Blotner S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57:6097–105.CrossRef
22.
Zurück zum Zitat Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127–37.CrossRef Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127–37.CrossRef
23.
24.
Zurück zum Zitat Ferri C, Giuggioli D, Colaci M. Renal manifestations of hepatitis C virus. Clin Liver Dis. 2017;21:487–97.CrossRef Ferri C, Giuggioli D, Colaci M. Renal manifestations of hepatitis C virus. Clin Liver Dis. 2017;21:487–97.CrossRef
Metadaten
Titel
Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy
verfasst von
Mohammad El-Sayed
Zeinab Abdellatif
Aisha Elsharkawy
Mohamed El Kassas
Reham Abd Elmoniem
Amaal Marzouk
Rabab Fouad
Gamal Esmat
Shereen Abdel Alem
Publikationsdatum
20.08.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2020
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-020-01505-5

Weitere Artikel der Ausgabe 6/2020

Infection 6/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.